Skip to main content

Advertisement

SpringerLink
Log in

Concomitant radiotherapy and transarterial chemoembolization reduce skeletal-related events related to bone metastases from renal cell carcinoma

  • Musculoskeletal
  • Published:
European Radiology Aims and scope Submit manuscript

Abstract

Objectives

The purpose of this study was to compare the efficacy of radiotherapy (RT) combined with transcatheter arterial chemoembolization (TACE) with RT alone for the treatment of bone metastases from renal cell carcinoma (RCC).

Methods

We included in this retrospective study 25 RCC patients (28 bone metastases), who were treated with RT at our institution. Patients were divided into two groups: patients treated with RT alone (monotherapy group; n = 17) and those treated with RT combined with TACE (combined therapy group; n = 11). The administered median RT dose was 30 Gy in 10 fractions. Anti-cancer agents used in TACE were cisplatin (median dose, 50 mg) and carboplatin (median dose, 240 mg) for patients with reduced renal function. We evaluated the objective response, post-RT-skeletal-related event (PR-SRE)–free rate, and adverse events associated with treatment for each group.

Results

The objective response rates for bone metastases in the monotherapy and combined therapy groups were 33% and 82%, respectively (p = 0.009). The 2-year PR-SRE-free rate in the monotherapy and combined therapy groups was 41.8% and 100%, respectively (p = 0.009). The objective response and PR-SRE-free rates were significantly superior in the combined therapy than in the monotherapy group. There were no significant differences in adverse events or survival between the two groups.

Conclusion

RT combined with TACE is a promising treatment for bone metastases from RCC, as it results in higher objective response, and PR-SRE-free rates compared with RT alone.

Key Points

• Skeletal-related events (SREs) are common in patients with bone metastases from renal cell carcinoma (RCC).

• Radiotherapy (RT) provides pain relief in patients with bone metastases from RCC, but rarely achieves objective response.

• Combination of RT with transcatheter arterial chemoembolization results in higher objective response and post-RT-SRE-free rates compared with RT alone and is a promising treatment for bone metastases from RCC, as it.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

BMA:

Bone-modifying agent

CR:

Complete response

CT:

Computed tomography

ICI:

Immune checkpoint inhibitor

MRI:

Magnetic resonance imaging

MTT:

Molecularly targeted therapy

PD:

Progressive disease

PR:

Partial response

PR-SRE:

Post-radiotherapy-skeletal-related event

QOL:

Quality of life

RCC:

Renal cell carcinoma

RT:

Radiotherapy

SR:

Stable response

SRE:

Skeletal-related event

TACE:

Transcatheter arterial chemoembolization

TAE:

Transcatheter arterial embolization

References

  1. Woodward E, Jagdev S, McParland L et al (2011) Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48:160–166

    Article  PubMed  Google Scholar 

  2. Bianchi M, Sun M, Jeldres C et al (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23:973–980

    Article  CAS  PubMed  Google Scholar 

  3. Beuselinck B, Oudard S, Rixe O et al (2011) Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 22:794–800

    Article  CAS  PubMed  Google Scholar 

  4. Santoni M, Conti A, Procopio G et al (2015) Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? J Exp Clin Cancer Res. https://doi.org/10.1186/s13046-015-0122-0

    Article  Google Scholar 

  5. McKay RR, Kroeger N, Xie W et al (2014) Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 65:577–584

    Article  PubMed  Google Scholar 

  6. Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590

    Article  CAS  PubMed  Google Scholar 

  7. Escudier B, Eiseen T, Stadler WM et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312–3318

    Article  CAS  PubMed  Google Scholar 

  8. Calvo E, Escudier B, Motzer RJ et al (2012) Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48:333–339

    Article  CAS  PubMed  Google Scholar 

  9. Bedke J, Stuhler V, Stenzl A, Brehmer B (2018) Immunotherapy for kidney cancer: status quo and the future. Curr Opin Urol 28:8–14

    Article  PubMed  Google Scholar 

  10. Teyssonneau D, Gross-Goupil M, Domblides C et al (2018) Treatment of spinal metastases in renal cell carcinoma: a critical review. Crit Rev Oncol Hematol 125:19–29

    Article  PubMed  Google Scholar 

  11. Lipton A, Zheng M, Seaman J (2003) Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98:962–969

    Article  CAS  PubMed  Google Scholar 

  12. Jung ST, Ghert MA, Harrelson JM, Scully SP (2003) Treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Relat Res 409:223–231

    Article  Google Scholar 

  13. Lee J, Hodgson D, Chow E et al (2005) A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. Cancer 104:1894–1900

    Article  PubMed  Google Scholar 

  14. Kijima T, Fujii Y, Suyama T et al (2008) Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int 103:620–624

    Article  PubMed  Google Scholar 

  15. Hosaka S, Katagiri H, Niwakawa M et al (2018) Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis. Int J Clin Oncol 23:1127–1133

    Article  CAS  PubMed  Google Scholar 

  16. Sun S, Lang EV (1998) Bone metastases from renal cell carcinoma: preoperative embolization. J Vasc Interv Radiol 9:263–269

    Article  CAS  PubMed  Google Scholar 

  17. Wirbel RJ, Roth R, Schlte M, Kramann B, Mutschler W (2005) Preoperative embolization in spinal and pelvic metastases. J Orthop Sci 10:253–257

    Article  PubMed  Google Scholar 

  18. Gupta P, Gamanagatti S (2012) Preoperative transarterial embolisation in bone tumors. World J Radiol 4:186–192

    Article  PubMed  Google Scholar 

  19. Radeleff B, Eiers M, Lopez-Benitez R et al (2006) Transarterial embolization of primary and secondary tumors of the skeletal system. Eur J Radiol 58:68–75

    Article  CAS  PubMed  Google Scholar 

  20. Forauer AR, Kent E, Cwikiel W, Esper P, Redman B (2007) Selective palliative transcatheter embolization of bony metastases from renal cell carcinoma. Acta Oncol 46:1012–1018

    Article  PubMed  Google Scholar 

  21. Nagata Y, Mitsumori M, Okajima K et al (1998) Transcatheter arterial embolization for malignant osseous and soft tissue sarcomas. II. Clinical results. Cardiovasc Intervent Radiol 21:208–213

    Article  CAS  PubMed  Google Scholar 

  22. Chiras J, Adem C, Vallee JN, Spelle L, Cormier E, Rose M (2004) Selective intra-arterial chemoembolization of pelvic and spine bone metastases. Eur Radiol 13:1774–1780

    Google Scholar 

  23. Koike Y, Takizawa K, Ogawa Y et al (2011) Transcatheter arterial chemoembolization (TACE) or embolization (TAE) for symptomatic bone metastases as a palliative treatment. Cardiovasc Intervent Radiol 34:793–801

    Article  PubMed  Google Scholar 

  24. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540

    Article  CAS  PubMed  Google Scholar 

  25. Diamond E, Molina AM, Carbonaro M et al (2015) Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy. Crit Rev Oncol Hematol 96:518–526

    Article  CAS  PubMed  Google Scholar 

  26. Hussain M, Vaishampayan U, Du W, Redman B, Smith DC (2001) Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19:2527–2533

    Article  CAS  PubMed  Google Scholar 

  27. Hosogoe S, Hatakeyama S, Kusaka A et al (2018) Platinum-based neoadjuvant chemotherapy improves oncological outcomes in patients with locally advanced upper tract urothelial carcinoma. Eur Urol Focus 4:946–953

    Article  PubMed  Google Scholar 

  28. Drooz AT, Lewis CA, Allen TE et al (2003) Quality improvement guidelines for percutaneous transcatheter embolization. J Vasc Interv Radiol 14:S237–S242

    PubMed  Google Scholar 

  29. Mizumoto M, Hrada H, Asakura H et al (2009) Radiotherapy for patients with metastases to the spinal column: a review of 603 patients at Shizuoka Cancer Center Hospital. Int J Radiat Oncol Biol Phys 79:208–213

    Article  Google Scholar 

  30. Soo CS, Wallace S, Chuang VP, Carrasco CH, Phillies G (1982) Lumbar artery embolization in cancer patients. Radiology 145:655–659

    Article  CAS  PubMed  Google Scholar 

  31. Uemura A, Fujimoto H, Yasuda S et al (2001) Transcatheter arterial embolization for bone metastases from hepatocellular carcinoma. Eur Radiol 11:1457–1462

    Article  CAS  PubMed  Google Scholar 

  32. Yamaura H, Yamada K, Matsuzawa T (1976) Radiation effect on the proliferating capillaries in rat transparent chambers. Int J Radiat Biol Relat Stud Phys Chem Med 30:179–187

    Article  CAS  PubMed  Google Scholar 

  33. Yamaura H, Matsuzawa T (1979) Tumor regrowth after irradiation: an experimental approach. Int J Radiat Biol Relat Stud Phys Chem Med 35:201–219

    Article  CAS  PubMed  Google Scholar 

  34. Coldwell DM, Stokes KR, Yakes WF (1994) Embolotherapy: agents, clinical applications and techniques. Radiographics 14:623–643

    Article  CAS  PubMed  Google Scholar 

  35. Kato T, Nemoto R, Mori H, Takahashi M, Harada M (1981) Arterial chemoembolization with mitomycin C microcapsules in the treatment of primary or secondary carcinoma of the kidney, liver bone and intrapelvic organs. Cancer 48:674–680

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was supported by a grant-in-aid of the Uruma Fund for the Promotion of Science.

Author information

Authors and Affiliations

  1. Department of Radiology, Graduate School of Medical Science University of The Ryukyus, 207, Uehara, Nishihara, Okinawa, 903-0215, Japan

    Joichi Heianna, Wataru Makino, Takuro Ariga, Kazuki Ishikawa, Takeaki Kusada, Hitoshi Maemoto, Masafumi Toguchi, Junji Ito, Yuko Iraha & Sadayuki Murayama

  2. Department of Urology, Graduate School of Medical Science University of The Ryukyus, 207, Uehara, Nishihara, Okinawa, 903-0215, Japan

    Masato Goya & Minoru Miyazato

Authors
  1. Joichi Heianna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wataru Makino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takuro Ariga
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazuki Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takeaki Kusada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hitoshi Maemoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masafumi Toguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Junji Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masato Goya
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Minoru Miyazato
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yuko Iraha
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Sadayuki Murayama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joichi Heianna.

Ethics declarations

Guarantor

The scientific guarantor of this publication is Sadayuki Murayama.

Conflict of interest

The authors declare that they have no conflict of interest.

Statistics and biometry

No complex statistical methods were necessary for this paper.

Informed consent

Written informed consent was obtained from all subjects (patients) in this study.

Ethical approval

Institutional Review Board approval was obtained.

Methodology

• retrospective

• observational

• performed at one institution

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heianna, J., Makino, W., Ariga, T. et al. Concomitant radiotherapy and transarterial chemoembolization reduce skeletal-related events related to bone metastases from renal cell carcinoma. Eur Radiol 30, 1525–1533 (2020). https://doi.org/10.1007/s00330-019-06454-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00330-019-06454-8

Keywords

Search

Navigation